Exposure in early and mid-pregnancy and late-onset preeclampsia
Any use of calcium-based antacids in gestational weeks 0-33 was not
associated with the risk of late-onset preeclampsia (adjusted RR 1.2
[95% CI 0.9-1.6]; Table 2). The results did not differ
substantially in the analyses on dosage or using the trajectories. An
increased risk of late-onset preeclampsia was observed for women who
used a low dose of calcium-based antacids (<1g/day) in
gestational weeks 0-16 (adjusted RR 1.8 [95% CI 1.1-2.9]) compared
to women who did not use calcium-based antacids in gestational weeks
0-16. An excess risk was not observed among women who used calcium-based
antacids in gestational weeks 17-33.
We did not observe clear associations between PPI use in gestational
weeks 0-33 and the risk of late-onset preeclampsia either. However,
late-onset preeclampsia seemed to occur more often among women who used
PPIs in gestational weeks 17-33 (4.8%) than among women who did not use
PPIs in these gestational weeks (2.5%; adjusted RR 1.6 [95% CI
1.0-2.8]).